What Is The Long-term Outlook for AMC Stock?
Meme stock extraordinaire AMC Entertainment Holdings, Inc. (NYSE:AMC) has long…
Sell
37
NONOF Quote, Financials, Valuation and Earnings
Last price:
$67.49
Seasonality move
:
6.24%
Day range:
$69.55 - $72.05
52-week range:
$55.28 - $149.55
Dividend yield:
2.36%
P/E ratio:
20.83x
P/S ratio:
7.19x
P/B ratio:
15.55x
Volume:
2.1K
Avg. volume:
126.2K
1-year change:
-50.65%
Market cap:
$312.5B
Revenue:
$42.1B
EPS (TTM):
$3.38
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Novo Nordisk AS has 35.35% upside to fair value with a price target of -- per share.
NONOF vs. S&P 500
-
Over the past 5 trading days, Novo Nordisk AS has underperformed the S&P 500 by -11.83% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Novo Nordisk AS does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novo Nordisk AS has grown year-over-year revenues for 19 quarters straight. In the most recent quarter Novo Nordisk AS reported revenues of $11B.
Earnings Growth
-
Novo Nordisk AS has grown year-over-year earnings for 11 quarters straight. In the most recent quarter Novo Nordisk AS reported earnings per share of $0.92.
Enterprise value:
323.7B
EV / Invested capital:
8.67x
Price / LTM sales:
7.19x
EV / EBIT:
16.17x
EV / Revenue:
7.43x
PEG ratio (5yr expected):
1.26x
EV / Free cash flow:
30.13x
Price / Operating cash flow:
29.17x
Enterprise value / EBITDA:
14.61x
Gross Profit (TTM):
$36.8B
Return On Assets:
25.78%
Net Income Margin (TTM):
34.52%
Return On Equity:
84.88%
Return On Invested Capital:
53.78%
Operating Margin:
49.68%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $26.4B | $35.5B | $43.6B | $9.5B | $11B | |
| Gross Profit | $22.2B | $30.1B | $36.8B | $8.1B | $9.2B | |
| Operating Income | $11.3B | $15.9B | $19.4B | $4.6B | $5.5B | |
| EBITDA | $11.7B | $18.2B | $22.1B | $5.4B | $6.5B | |
| Diluted EPS | $1.90 | $2.90 | $3.38 | $0.83 | $0.92 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $9.7B | $13B | $16.7B | $16.8B | $25.3B | |
| Total Assets | $22.3B | $29.6B | $36.6B | $43.2B | $71B | |
| Current Liabilities | $11.4B | $14.3B | $19.3B | $24B | $34.3B | |
| Total Liabilities | $13.1B | $19.6B | $24.9B | $28.9B | $50.9B | |
| Total Equity | $9.2B | $10B | $11.7B | $14.3B | $20.1B | |
| Total Debt | $1.5B | $3.8B | $3.7B | $3.9B | $17.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $11.9B | $13.6B | $18.9B | $2.1B | $3.5B | |
| Cash From Investing | -$4.2B | -$4.8B | -$20.2B | $576.2M | -$940.8M | |
| Cash From Financing | -$7.4B | -$10B | $5.9B | -$3.8B | $768.5M | |
| Free Cash Flow | $9.4B | $7.3B | $10.7B | $772.7M | $1.4B | |
NONOF
Sector
Market Cap
$312.5B
$32.8M
Price % of 52-Week High
47.03%
46.28%
Dividend Yield
2.36%
0%
Shareholder Yield
2.37%
-0.74%
1-Year Price Total Return
-50.65%
-35.38%
Beta (5-Year)
0.661
0.632
Dividend yield:
2.36%
Annualized payout:
$1.45
Payout ratio:
47.98%
Growth streak:
4 years
Technicals
8-day SMA
Sell
Level
$75.32
200-day SMA
Sell
Level
$90.64
Bollinger Bands (100)
Sell
Level
64.64 - 82.72
Chaikin Money Flow
Buy
Level
686.9K
20-day SMA
Sell
Level
$73.69
Relative Strength Index (RSI14)
Sell
Level
45.55
ADX Line
Sell
Level
14.63
Williams %R
Buy
Level
-81.1824
50-day SMA
Buy
Level
$68.22
MACD (12, 26)
Buy
Level
1.35
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
5.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.9761)
Buy
CA Score
(Annual)
Level (0.5179)
Buy
Beneish M-Score
(Annual)
Level (-2.48)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-1.1143)
Buy
Piotroski F Score
(Annual)
Level (5)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Stock Forecast FAQ
In the current month, NONOF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NONOF average analyst price target in the past 3 months is --.
-
Where Will Novo Nordisk AS Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novo Nordisk AS share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Novo Nordisk AS?
Analysts are divided on their view about Novo Nordisk AS share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Novo Nordisk AS is a Sell and believe this share price will drop from its current level to --.
-
What Is Novo Nordisk AS's Price Target?
The price target for Novo Nordisk AS over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NONOF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novo Nordisk AS is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of NONOF?
You can purchase shares of Novo Nordisk AS via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novo Nordisk AS shares.
-
What Is The Novo Nordisk AS Share Price Today?
Novo Nordisk AS was last trading at $67.49 per share. This represents the most recent stock quote for Novo Nordisk AS. Yesterday, Novo Nordisk AS closed at $70.33 per share.
-
How To Buy Novo Nordisk AS Stock Online?
In order to purchase Novo Nordisk AS stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NuScale the Best Nuclear Stock to Buy?
NuScale Power (NYSE:SMR) is a nuclear power startup that has…
Where Will Kestra Medical Stock Be in 1 Year?
Kestra Medical Technologies (NASDAQ:KMTS) is a medical device startup that…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 42x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 50x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
58
AMBA alert for Jun 25
Ambarella [AMBA] is up 4.36% over the past day.
Buy
65
EXOD alert for Jun 25
Exodus Movement [EXOD] is down 9.63% over the past day.
Buy
78
SMR alert for Jun 25
NuScale Power [SMR] is down 10.59% over the past day.
